Turns out pharma companies can spare a dime (or more) for cancer patients who want to participate in clinical trials. Pennsylvania recently became the 2nd state (after California) to sign a bill that “provides for reimbursement of patient expenses associated with participation in cancer clinical trials.” Wait, we need a bill for that? Guess so. The participation rate for people with cancer in the US is really low, like 3% low. Maybe these bills will create some positive momentum for clinical trial participation. Just a 1% increase in participation rates would be huge, given there are over 1,000 assets in the development pipeline targeting cancer. Apparently FDA came out with some guidance that reads “paying research subjects in exchange for their participation is a common and, in general, acceptable practice.” Good to know.